The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

This was the stock's second consecutive day of losses.

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

This was the stock's second consecutive day of gains.

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...